Slide 1: Co-formulation of ASC36 and ASC35 Demonstrated Superior Weight Loss in DIO Rats
Co-formulation of ASC36 and ASC35, Once-Monthly Amylin Receptor Agonist and GLP-1R/GIPR Agonist, Demonstrated Superior Weight Loss to Eloralintide/Tirzepatide Combo in DIO Rats Conclusion • ASC36 is a once-monthly to once-quarterly next-generation amylin receptor agonist peptide. • ASC35 is a once-m
Slide 2: ASC36 and ASC35 Monotherapy in DIO models
ASC36 and ASC35 Monotherapy in DIO models Study 1: ASC36 vs Petrelintide in DIO Rats Study 2: ASC36 vs Eloralintide in DIO Rats Study 3: ASC35 vs Tirzepatide in DIO mouse 91% increase than Petrelintide 32% increase than Eloralintide 71% increase than Tirzepatide
Slide 3: Weight Loss of ASC36_35 Co-formulation in DIO Rats
Weight Loss of ASC36_35 Co-formulation in DIO Rats Study 1 Accumulated food intake(g ASC36_35 co-formulation demonstrates additive food intake suppression and achieves 39% Note: greater body weight reduction than ASC35 monotherapy 1. HFD: High Fat Diet 2. SQ: Subcutaneous(ly) 3. Q2D: Every other day
Slide 4: Weight Loss of ASC36_35 Co-formulation in DIO Rats
Weight Loss of ASC36_35 Co-formulation in DIO Rats Study 2 Note: ASC36_35 co-formulation exhibits an additional 98% greater weight loss than 1. HFD: High Fat Diet 2. SQ: Subcutaneous(ly) 3. Q2D: Every other day eloralintide /tirzepatide co-formulation
Slide 5: Weight Loss of ASC36_35 Co-formulation in NHPs
Weight Loss of ASC36_35 Co-formulation in NHPs Study 3 ASC36_35 co-formulation demonstrates dose-dependent weight loss in NHPs
Slide 6: Fibrillation study PK Profile in NHPs
Fibrillation study PK Profile in NHPs Fibrotic aggregation ASC36_35 co-formulation 150 100 50 0 0 24 48 72 96 120 144 168 Time (h) Cagrilintide in pH7.5 HEPES buffer ASC36_35 co-formulation in solution332 (0.25 / 0.5 mg/kg): analyte ASC35 ASC36_35 co-formulation (2.5 mg/mL / 5 mg/mL) in solution197,
Slide 7: ASC36_35 Co-formulation Summary
ASC36_35 Co-formulation Summary • ASC36 is a once-monthly to once-quarterly next-generation amylin receptor agonist peptide. ASC35 is a once-monthly to once-quarterly GLP-1R/GIPR agonist peptide. • ASC36_35 co-formulation demonstrates marked body weight reduction in DIO rats and NHPs. • ASC36_35 co-
Slide 8: E-poster
CO) BRAL ascletis, Co-formulation of ASC36 and ASC35, Once-Monthly Amylin Receptor Agonist and GLP-1R/GIPR Agonist, Demonstrated Superior Weight Loss to Eloralintide/Tirzepatide Combo in DIO Rats Jinzi Jason Wu and Chengfei Wu Iniroduction ‘Ascets Pharma (China) Co, Lined, Hong Kang Fixed-dose combi